| Robert Jason Gruttadauria, PT | |
|
49 Seekonk St, Providence, RI 02906-5176 | |
| (401) 230-1126 | |
| (401) 230-1128 |
| Full Name | Robert Jason Gruttadauria |
|---|---|
| Gender | Male |
| Speciality | Physical Therapy |
| Experience | 12 Years |
| Location | 49 Seekonk St, Providence, Rhode Island |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1093062804 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225100000X | Physical Therapist | PT02498 (Rhode Island) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Silver Fern Practice Llc | 1658266515 | 120 |
News Archive
Oncolytics Biotech Inc. announced today that following submission to the U.S. Food and Drug Administration for review, the Company is initiating a U.S. Phase I study of REOLYSIN(R) in combination with FOLFIRI (Folinic Acid (leucovorin) + Fluorouracil (5-FU) + Irinotecan) in patients with oxaliplatin refractory/intolerant Kras mutant colorectal cancer.
United Therapeutics Corporation announced today the completion of its FREEDOM-M Phase 3 trial of treprostinil diethanolamine, an investigational sustained release oral formulation of treprostinil, a stable synthetic form of prostacyclin, in patients with pulmonary arterial hypertension (PAH).
A research group including Professor MATSUDA Tetsuya of Tamagawa University's Brain Science Institute (Machida City, Tokyo; Director: SAKAGAMI Masamichi) and Assistant Professor ISHIHARA Toru from Kobe University's Graduate School of Human Development and Environment has illuminated the changes in the brain's neural network and cortex structure that underlie the positive association between childhood exercise and the maintenance and promotion of cognitive function in later life.
Bioheart, Inc., announced today plans for establishing two Centers of Excellence in the Middle East to provide its cell therapy procedures to patients suffering from congestive heart failure and peripheral arterial disease. Dr. Karl E. Groth, Chairman and CEO, and Peggy A. Farley, Chief Operating and Financial Officer, are now in that region holding discussions and performing site inspections.
Zynx Health CEO and President Scott Weingarten, MD, MPH will be speaking at IHI on clinical decision support, specifically focusing on the implications of clinical decision support for meaningful use of EHRs and American Recovery Reinvestment Act (ARRA) funding. Zynx is the leader in evidence-based and experience-based clinical decision support.
› Verified 7 days ago
| Provider Name | Silver Fern Practice Llc |
|---|---|
| Provider Type | Part B Supplier - Physical/occupational Therapy Group In Private Practice |
| Provider Identifiers | NPI Number: 1851472914 PECOS PAC ID: 1658266515 Enrollment ID: O20120813000580 |
News Archive
Oncolytics Biotech Inc. announced today that following submission to the U.S. Food and Drug Administration for review, the Company is initiating a U.S. Phase I study of REOLYSIN(R) in combination with FOLFIRI (Folinic Acid (leucovorin) + Fluorouracil (5-FU) + Irinotecan) in patients with oxaliplatin refractory/intolerant Kras mutant colorectal cancer.
United Therapeutics Corporation announced today the completion of its FREEDOM-M Phase 3 trial of treprostinil diethanolamine, an investigational sustained release oral formulation of treprostinil, a stable synthetic form of prostacyclin, in patients with pulmonary arterial hypertension (PAH).
A research group including Professor MATSUDA Tetsuya of Tamagawa University's Brain Science Institute (Machida City, Tokyo; Director: SAKAGAMI Masamichi) and Assistant Professor ISHIHARA Toru from Kobe University's Graduate School of Human Development and Environment has illuminated the changes in the brain's neural network and cortex structure that underlie the positive association between childhood exercise and the maintenance and promotion of cognitive function in later life.
Bioheart, Inc., announced today plans for establishing two Centers of Excellence in the Middle East to provide its cell therapy procedures to patients suffering from congestive heart failure and peripheral arterial disease. Dr. Karl E. Groth, Chairman and CEO, and Peggy A. Farley, Chief Operating and Financial Officer, are now in that region holding discussions and performing site inspections.
Zynx Health CEO and President Scott Weingarten, MD, MPH will be speaking at IHI on clinical decision support, specifically focusing on the implications of clinical decision support for meaningful use of EHRs and American Recovery Reinvestment Act (ARRA) funding. Zynx is the leader in evidence-based and experience-based clinical decision support.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Robert Jason Gruttadauria, PT 4 Richmond Sq Ste 200, Providence, RI 02906-5117 Ph: (401) 433-4172 | Robert Jason Gruttadauria, PT 49 Seekonk St, Providence, RI 02906-5176 Ph: (401) 230-1126 |
News Archive
Oncolytics Biotech Inc. announced today that following submission to the U.S. Food and Drug Administration for review, the Company is initiating a U.S. Phase I study of REOLYSIN(R) in combination with FOLFIRI (Folinic Acid (leucovorin) + Fluorouracil (5-FU) + Irinotecan) in patients with oxaliplatin refractory/intolerant Kras mutant colorectal cancer.
United Therapeutics Corporation announced today the completion of its FREEDOM-M Phase 3 trial of treprostinil diethanolamine, an investigational sustained release oral formulation of treprostinil, a stable synthetic form of prostacyclin, in patients with pulmonary arterial hypertension (PAH).
A research group including Professor MATSUDA Tetsuya of Tamagawa University's Brain Science Institute (Machida City, Tokyo; Director: SAKAGAMI Masamichi) and Assistant Professor ISHIHARA Toru from Kobe University's Graduate School of Human Development and Environment has illuminated the changes in the brain's neural network and cortex structure that underlie the positive association between childhood exercise and the maintenance and promotion of cognitive function in later life.
Bioheart, Inc., announced today plans for establishing two Centers of Excellence in the Middle East to provide its cell therapy procedures to patients suffering from congestive heart failure and peripheral arterial disease. Dr. Karl E. Groth, Chairman and CEO, and Peggy A. Farley, Chief Operating and Financial Officer, are now in that region holding discussions and performing site inspections.
Zynx Health CEO and President Scott Weingarten, MD, MPH will be speaking at IHI on clinical decision support, specifically focusing on the implications of clinical decision support for meaningful use of EHRs and American Recovery Reinvestment Act (ARRA) funding. Zynx is the leader in evidence-based and experience-based clinical decision support.
› Verified 7 days ago
Conor D. Bray, P.T., D.P.T Physical Therapist Medicare: Medicare Enrolled Practice Location: 49 Seekonk St, Providence, RI 02906 Phone: 401-726-7100 | |
Nicholas Ford, DPT Physical Therapist Medicare: Medicare Enrolled Practice Location: 49 Seekonk St, Providence, RI 02906 Phone: 401-726-7100 | |
Mr. Thomas H. Wheeler, MMSC, PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 830 Chalkstone Ave, Providence, RI 02908 Phone: 401-273-7100 | |
Mrs. Erin Kelli Dasilva, DPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 765 Allens Ave, Providence, RI 02905 Phone: 401-444-5020 Fax: 401-444-4181 | |
Angela Marie Lostritto, DPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 49 Seekonk St, Providence, RI 02906 Phone: 401-230-1126 | |
Alaina Lynn Denoncour, PT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 285 Promenade St, Providence, RI 02908 Phone: 401-459-4001 Fax: 401-459-4006 | |
Eileen T Tainsh, Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 593 Eddy St, George Clinic, Providence, RI 02903 Phone: 401-444-3201 Fax: 401-444-6115 |